Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2016 | Pages:
49 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Pipeline Review, H1 2016', provides in depth analysis on Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) targeted pipeline therapeutics. The report provides comprehensive information on the Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - The report reviews Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) targeted therapeutics and enlists all their major and minor projects - The report assesses Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) Overview 6 Therapeutics Development 7 Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Products under Development by Stage of Development 7 Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Products under Development by Therapy Area 8 Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Products under Development by Indication 9 Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Products under Development by Companies 12 Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Therapeutics Assessment 14 Assessment by Monotherapy/Combination Products 14 Assessment by Mechanism of Action 15 Assessment by Route of Administration 16 Assessment by Molecule Type 17 Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Companies Involved in Therapeutics Development 18 Amura Holdings Limited 18 Medivir AB 19 Merck & Co., Inc. 20 Virobay Inc. 21 Wroclawskie Centrum Badan EIT+ Sp. z o.o. 22 Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Drug Profiles 23 AM-3701 - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 AM-3876 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 MIV-711 - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 odanacatib - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 Small Molecules to Inhibit CTSK for Oncology - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 VBY-129 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 VBY-285 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Dormant Projects 33 Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Discontinued Products 34 Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Featured News & Press Releases 35 Jan 28, 2016: Medivir initiates phase IIa study of MIV-711 in knee osteoarthritis 35 Sep 15, 2014: Merck Announces Data from Pivotal Phase 3 Fracture Outcomes Study for Odanacatib, an Investigational Oral, Once-Weekly Treatment for Osteoporosis 35 Oct 09, 2013: Medivir: Positive results from a phase I study with MIV-711 for the treatment of osteoarthritis and other bone related disorders 37 May 21, 2013: Medivir Presents Positive Results From Phase Ia Study With MIV-711 For Treatment Of Skeletal Disorders At 2013 ECTS Annual Meeting 38 Oct 13, 2012: Merck Announces Results From Phase II Clinical Trial Of Odanacatib In Post-Menopausal Osteoporosis 39 Aug 21, 2012: Medivir Commences Phase Ib Trial Of MIV-711 For Treatment Of Skeletal Disorders 40 Jul 11, 2012: Merck Provides Update On Phase III Trial Of Odanacatib For Treatment Of Osteoporosis 40 May 28, 2012: Medivir Initiates Phase I Clinical Trial Of MIV-711 For Treatment Of Bone Disorders 41 Mar 19, 2012: Medivir To File Application For Initiation Of Phase I Trials Of MIV-711 42 Sep 19, 2011: Merck Announces Presentation Of New Data On Odanacatib Phase III Investigational Cat-K Inhibitor For Osteoporosis At Annual Meeting Of American Society For Bone And Mineral Research 42 Oct 18, 2010: Merck Presents New Data On Odanacatib For Treatment of Osteoporosis In Postmenopausal Women at ASBMR Annual Meeting 44 Sep 16, 2009: Medivir Presented Its Cathepsin K Program at the Ongoing 31st Asbmr Meeting in Denver, USA 45 Sep 14, 2009: New, Long-Term Data For Odanacatib, Merck's Investigational Cat K Inhibitor, Showed Positive Results In Treating Osteoporosis 46 Sep 01, 2009: Medivir Broadens Its Bone Disease Portfolio By Designating One Further Candidate Drug (CD), MIV-711 46 Sep 16, 2008: Odanacatib, Merck's Investigational Cathepsin K Inhibitor, Increased Bone Mineral Density (BMD) Over Two Years At Key Fracture Sites In Phase IIB Study 46 Appendix 48 Methodology 48 Coverage 48 Secondary Research 48 Primary Research 48 Expert Panel Validation 48 Contact Us 48 Disclaimer 49
List of Tables
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Products under Development by Companies, H1 2016 13 Assessment by Monotherapy/Combination Products, H1 2016 14 Number of Products by Stage and Mechanism of Action, H1 2016 15 Number of Products by Stage and Route of Administration, H1 2016 16 Number of Products by Stage and Molecule Type, H1 2016 17 Pipeline by Amura Holdings Limited, H1 2016 18 Pipeline by Medivir AB, H1 2016 19 Pipeline by Merck & Co., Inc., H1 2016 20 Pipeline by Virobay Inc., H1 2016 21 Pipeline by Wroclawskie Centrum Badan EIT+ Sp. z o.o., H1 2016 22 Dormant Projects, H1 2016 33 Discontinued Products, H1 2016 34
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
